Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Type: 2024 VS 2022 VS 2034
1.2.2 Pleuromutilin
1.2.3 Cephalosporin
1.2.4 Glycylcycline
1.2.5 Oxazolidinone
1.2.6 Ketolide
1.3 Market by Application
1.3.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth by Application: 2024 VS 2022 VS 2034
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Perspective (2024-2034)
2.2 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Growth Trends by Region
2.2.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region: 2024 VS 2022 VS 2034
2.2.2 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Historic Market Size by Region (2024-2024)
2.2.3 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Region (2024-2034)
2.3 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Dynamics
2.3.1 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Industry Trends
2.3.2 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Drivers
2.3.3 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Challenges
2.3.4 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players by Revenue
3.1.1 Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players by Revenue (2024-2024)
3.1.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Players (2024-2024)
3.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue
3.4 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Concentration Ratio
3.4.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue in 2022
3.5 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Key Players Head office and Area Served
3.6 Key Players Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product Solution and Service
3.7 Date of Enter into Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Breakdown Data by Type
4.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Historic Market Size by Type (2024-2024)
4.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Type (2024-2034)
5 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Breakdown Data by Application
5.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Historic Market Size by Application (2024-2024)
5.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2024-2034)
6.2 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Country: 2024 VS 2022 VS 2034
6.3 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2024)
6.4 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2024-2034)
7.2 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Country: 2024 VS 2022 VS 2034
7.3 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2024)
7.4 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2024-2034)
8.2 Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Region: 2024 VS 2022 VS 2034
8.3 Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2024-2024)
8.4 Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2024-2034)
9.2 Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Country: 2024 VS 2022 VS 2034
9.3 Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2024)
9.4 Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (2024-2034)
10.2 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Growth Rate by Country: 2024 VS 2022 VS 2034
10.3 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2024)
10.4 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Nabriva Therapeutics
11.1.1 Nabriva Therapeutics Company Detail
11.1.2 Nabriva Therapeutics Business Overview
11.1.3 Nabriva Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.1.4 Nabriva Therapeutics Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.1.5 Nabriva Therapeutics Recent Development
11.2 Melinta Therapeutics
11.2.1 Melinta Therapeutics Company Detail
11.2.2 Melinta Therapeutics Business Overview
11.2.3 Melinta Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.2.4 Melinta Therapeutics Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.2.5 Melinta Therapeutics Recent Development
11.3 Wakunaga Pharmaceutical
11.3.1 Wakunaga Pharmaceutical Company Detail
11.3.2 Wakunaga Pharmaceutical Business Overview
11.3.3 Wakunaga Pharmaceutical Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.3.4 Wakunaga Pharmaceutical Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.3.5 Wakunaga Pharmaceutical Recent Development
11.4 Forest Pharmaceuticals
11.4.1 Forest Pharmaceuticals Company Detail
11.4.2 Forest Pharmaceuticals Business Overview
11.4.3 Forest Pharmaceuticals Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.4.4 Forest Pharmaceuticals Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.4.5 Forest Pharmaceuticals Recent Development
11.5 Pfizer, Paratek Pharmaceuticals,
11.5.1 Pfizer, Paratek Pharmaceuticals, Company Detail
11.5.2 Pfizer, Paratek Pharmaceuticals, Business Overview
11.5.3 Pfizer, Paratek Pharmaceuticals, Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.5.4 Pfizer, Paratek Pharmaceuticals, Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.5.5 Pfizer, Paratek Pharmaceuticals, Recent Development
11.6 Cumberland Pharmaceuticals Inc.
11.6.1 Cumberland Pharmaceuticals Inc. Company Detail
11.6.2 Cumberland Pharmaceuticals Inc. Business Overview
11.6.3 Cumberland Pharmaceuticals Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.6.4 Cumberland Pharmaceuticals Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.6.5 Cumberland Pharmaceuticals Inc. Recent Development
11.7 Theravance Biopharma
11.7.1 Theravance Biopharma Company Detail
11.7.2 Theravance Biopharma Business Overview
11.7.3 Theravance Biopharma Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.7.4 Theravance Biopharma Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.7.5 Theravance Biopharma Recent Development
11.8 Merck Sharp & Dohme Inc.
11.8.1 Merck Sharp & Dohme Inc. Company Detail
11.8.2 Merck Sharp & Dohme Inc. Business Overview
11.8.3 Merck Sharp & Dohme Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.8.4 Merck Sharp & Dohme Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.8.5 Merck Sharp & Dohme Inc. Recent Development
11.9 Cubist Pharmaceuticals LLC
11.9.1 Cubist Pharmaceuticals LLC Company Detail
11.9.2 Cubist Pharmaceuticals LLC Business Overview
11.9.3 Cubist Pharmaceuticals LLC Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.9.4 Cubist Pharmaceuticals LLC Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.9.5 Cubist Pharmaceuticals LLC Recent Development
11.10 Shionogi Inc.
11.10.1 Shionogi Inc. Company Detail
11.10.2 Shionogi Inc. Business Overview
11.10.3 Shionogi Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.10.4 Shionogi Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.10.5 Shionogi Inc. Recent Development
11.11 Allergan, Eagle Pharmaceutical Inc.
11.11.1 Allergan, Eagle Pharmaceutical Inc. Company Detail
11.11.2 Allergan, Eagle Pharmaceutical Inc. Business Overview
11.11.3 Allergan, Eagle Pharmaceutical Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.11.4 Allergan, Eagle Pharmaceutical Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.11.5 Allergan, Eagle Pharmaceutical Inc. Recent Development
11.12 Combioxin SA
11.12.1 Combioxin SA Company Detail
11.12.2 Combioxin SA Business Overview
11.12.3 Combioxin SA Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.12.4 Combioxin SA Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.12.5 Combioxin SA Recent Development
11.13 Takeda
11.13.1 Takeda Company Detail
11.13.2 Takeda Business Overview
11.13.3 Takeda Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.13.4 Takeda Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.13.5 Takeda Recent Development
11.14 TiGenix
11.14.1 TiGenix Company Detail
11.14.2 TiGenix Business Overview
11.14.3 TiGenix Community Acquired Bacterial Pneumonia(CABP) Therapeutics Introduction
11.14.4 TiGenix Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
11.14.5 TiGenix Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Type (US$ Million): 2024 VS 2022 VS 2034
Table 2. Key Players of Pleuromutilin
Table 3. Key Players of Cephalosporin
Table 4. Key Players of Glycylcycline
Table 5. Key Players of Oxazolidinone
Table 6. Key Players of Ketolide
Table 7. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth by Application (US$ Million): 2024 VS 2022 VS 2034
Table 8. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 9. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2024-2024) & (US$ Million)
Table 10. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Region (2024-2024)
Table 11. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 12. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Region (2024-2034)
Table 13. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Trends
Table 14. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Drivers
Table 15. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Challenges
Table 16. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Restraints
Table 17. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue by Players (2024-2024) & (US$ Million)
Table 18. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Players (2024-2024)
Table 19. Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics as of 2022)
Table 20. Ranking of Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (CR5 and HHI) & (2024-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product Solution and Service
Table 24. Date of Enter into Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Type (2024-2024) & (US$ Million)
Table 27. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Type (2024-2024)
Table 28. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 29. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Type (2024-2034)
Table 30. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Application (2024-2024) & (US$ Million)
Table 31. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Application (2024-2024)
Table 32. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 33. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Application (2024-2034)
Table 34. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 35. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2024) & (US$ Million)
Table 36. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 37. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 38. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2024) & (US$ Million)
Table 39. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 40. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Region (US$ Million): 2024 VS 2022 VS 2034
Table 41. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2024-2024) & (US$ Million)
Table 42. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Region (2024-2034) & (US$ Million)
Table 43. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 44. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2024) & (US$ Million)
Table 45. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 46. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 47. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2024) & (US$ Million)
Table 48. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 49. Nabriva Therapeutics Company Detail
Table 50. Nabriva Therapeutics Business Overview
Table 51. Nabriva Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 52. Nabriva Therapeutics Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 53. Nabriva Therapeutics Recent Development
Table 54. Melinta Therapeutics Company Detail
Table 55. Melinta Therapeutics Business Overview
Table 56. Melinta Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 57. Melinta Therapeutics Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 58. Melinta Therapeutics Recent Development
Table 59. Wakunaga Pharmaceutical Company Detail
Table 60. Wakunaga Pharmaceutical Business Overview
Table 61. Wakunaga Pharmaceutical Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 62. Wakunaga Pharmaceutical Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 63. Wakunaga Pharmaceutical Recent Development
Table 64. Forest Pharmaceuticals Company Detail
Table 65. Forest Pharmaceuticals Business Overview
Table 66. Forest Pharmaceuticals Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 67. Forest Pharmaceuticals Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 68. Forest Pharmaceuticals Recent Development
Table 69. Pfizer, Paratek Pharmaceuticals, Company Detail
Table 70. Pfizer, Paratek Pharmaceuticals, Business Overview
Table 71. Pfizer, Paratek Pharmaceuticals, Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 72. Pfizer, Paratek Pharmaceuticals, Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 73. Pfizer, Paratek Pharmaceuticals, Recent Development
Table 74. Cumberland Pharmaceuticals Inc. Company Detail
Table 75. Cumberland Pharmaceuticals Inc. Business Overview
Table 76. Cumberland Pharmaceuticals Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 77. Cumberland Pharmaceuticals Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 78. Cumberland Pharmaceuticals Inc. Recent Development
Table 79. Theravance Biopharma Company Detail
Table 80. Theravance Biopharma Business Overview
Table 81. Theravance Biopharma Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 82. Theravance Biopharma Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 83. Theravance Biopharma Recent Development
Table 84. Merck Sharp & Dohme Inc. Company Detail
Table 85. Merck Sharp & Dohme Inc. Business Overview
Table 86. Merck Sharp & Dohme Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 87. Merck Sharp & Dohme Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 88. Merck Sharp & Dohme Inc. Recent Development
Table 89. Cubist Pharmaceuticals LLC Company Detail
Table 90. Cubist Pharmaceuticals LLC Business Overview
Table 91. Cubist Pharmaceuticals LLC Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 92. Cubist Pharmaceuticals LLC Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 93. Cubist Pharmaceuticals LLC Recent Development
Table 94. Shionogi Inc. Company Detail
Table 95. Shionogi Inc. Business Overview
Table 96. Shionogi Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 97. Shionogi Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 98. Shionogi Inc. Recent Development
Table 99. Allergan, Eagle Pharmaceutical Inc. Company Detail
Table 100. Allergan, Eagle Pharmaceutical Inc. Business Overview
Table 101. Allergan, Eagle Pharmaceutical Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 102. Allergan, Eagle Pharmaceutical Inc. Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 103. Allergan, Eagle Pharmaceutical Inc. Recent Development
Table 104. Combioxin SA Company Detail
Table 105. Combioxin SA Business Overview
Table 106. Combioxin SA Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 107. Combioxin SA Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 108. Combioxin SA Recent Development
Table 109. Takeda Company Detail
Table 110. Takeda Business Overview
Table 111. Takeda Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 112. Takeda Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 113. Takeda Recent Development
Table 114. TiGenix Company Detail
Table 115. TiGenix Business Overview
Table 116. TiGenix Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product
Table 117. TiGenix Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024) & (US$ Million)
Table 118. TiGenix Recent Development
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Type: 2022 VS 2034
Figure 3. Pleuromutilin Features
Figure 4. Cephalosporin Features
Figure 5. Glycylcycline Features
Figure 6. Oxazolidinone Features
Figure 7. Ketolide Features
Figure 8. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Application: 2022 VS 2034
Figure 10. Hospital Pharmacy Case Studies
Figure 11. Retail Pharmacy Case Studies
Figure 12. Online Pharmacy Case Studies
Figure 13. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Report Years Considered
Figure 14. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size (US$ Million), Year-over-Year: 2024-2034
Figure 15. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size, (US$ Million), 2024 VS 2022 VS 2034
Figure 16. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Region: 2022 VS 2034
Figure 17. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Players in 2022
Figure 18. Global Top Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue in 2022
Figure 20. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 21. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Country (2024-2034)
Figure 22. United States Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 23. Canada Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 24. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 25. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Country (2024-2034)
Figure 26. Germany Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 27. France Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 28. U.K. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 29. Italy Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 30. Russia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 31. Nordic Countries Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 32. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 33. Asia-Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Region (2024-2034)
Figure 34. China Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 35. Japan Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 36. South Korea Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 37. Southeast Asia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 38. India Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 39. Australia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 40. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 41. Latin America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Country (2024-2034)
Figure 42. Mexico Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 43. Brazil Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 44. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 45. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Country (2024-2034)
Figure 46. Turkey Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 47. Saudi Arabia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 48. Nabriva Therapeutics Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 49. Melinta Therapeutics Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 50. Wakunaga Pharmaceutical Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 51. Forest Pharmaceuticals Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 52. Pfizer, Paratek Pharmaceuticals, Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 53. Cumberland Pharmaceuticals Inc. Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 54. Theravance Biopharma Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 55. Merck Sharp & Dohme Inc. Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 56. Cubist Pharmaceuticals LLC Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 57. Shionogi Inc. Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 58. Allergan, Eagle Pharmaceutical Inc. Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 59. Combioxin SA Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 60. Takeda Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 61. TiGenix Revenue Growth Rate in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business (2024-2024)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed